Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?